Medical Science Liaison/Sr. Medical Science Liaison, Oncology - Northeast Region

Remote

Apply with AI Apply

Not SpecifiedCompensation

Senior (5 to 8 years), Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

Pharmaceuticals, Biotechnology, HealthcareIndustries

Requirements

Candidates should possess strong scientific oncology acumen, including knowledge of therapeutic landscapes, NCCN guidelines, clinical trial data, oncology cooperative groups, and NCI/NCCN cancer centers. They must demonstrate intellectual curiosity, adaptability to change, teamwork, strong communication skills, results-orientation, decision-making abilities, and clinical and scientific expertise. A working knowledge of the drug development process across various functions like research, development, clinical operations, biostatistics, regulatory, and commercial is also required. The role necessitates approximately 50-60% travel.

Responsibilities

The Medical Science Liaison will engage in scientific discussions with thought leaders in gynecological oncology and other malignancies to educate them about Corcept and cortisol modulation in oncology. They will proactively communicate and educate healthcare professionals on disease states where cortisol modulation may be relevant, provide scientific exchange on Corcept's data and development plans, and develop relationships with thought leaders, patient advocacy groups, and oncology associations. Responsibilities also include capturing and communicating insights from the medical community to inform company decisions, supporting company-sponsored and investigator-initiated studies, scientific communications, publications, education, advisory boards, and congresses. Maintaining high standards of scientific, clinical, and technical expertise and demonstrating teamwork and collaboration within Medical Affairs and cross-functionally are essential.

Skills

Oncology

Cortisol Modulation

Gynecological Oncology

Scientific Discussions

Thought Leader Engagement

Insight Gathering

Scientific Education

Healthcare Professional Education

Corcept Therapeutics

Develops cortisol modulators for medical conditions

About Corcept Therapeutics

Corcept Therapeutics focuses on developing treatments that regulate cortisol levels in the body, which is important for managing various health issues. Their main product, Korlym, is used to treat Cushing's syndrome, a condition caused by too much cortisol. Korlym was approved by the FDA in 2012 and is the first medication specifically for this disorder. Corcept stands out from competitors by having a strong emphasis on research and development, having discovered over 1,000 unique cortisol modulators. The company aims to expand its range of treatments while also providing educational resources to healthcare professionals and patients to improve understanding and care for cortisol-related conditions.

Menlo Park, CaliforniaHeadquarters

1998Year Founded

$39.7MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

201-500Employees

Benefits

Remote Work Options

Flexible Work Hours

Risks

Teva's antitrust lawsuit could lead to legal expenses and market share loss.

Heavy reliance on Korlym makes Corcept vulnerable to market fluctuations.

Recent investments may pressure Corcept for short-term financial performance, impacting R&D.

Differentiation

Corcept specializes in cortisol modulation, a niche with few direct competitors.

Korlym is the first FDA-approved treatment for Cushing's syndrome, a significant market advantage.

Corcept's extensive R&D has led to the discovery of over 1,000 selective cortisol modulators.

Upsides

Increased interest in cortisol therapies for mental health boosts Corcept's R&D prospects.

Advancements in drug delivery systems could enhance Corcept's product efficacy.

The FDA's fast-track designation supports Corcept's innovative cortisol-related treatments.

Land your dream remote job 3x faster with AI

Try Jobo Free